JNJ - Johnson & Johnson
After hours:
| Previous close | 154.41 |
| Open | 154.69 |
| Bid | 154.20 x 800 |
| Ask | 154.60 x 900 |
| Day's range | 154.20 - 155.27 |
| 52-week range | 150.11 - 183.35 |
| Volume | |
| Avg. volume | 7,209,479 |
| Market cap | 401.114B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 32.36 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.76 (3.08%) |
| Ex-dividend date | 22 May 2023 |
| 1y target est | N/A |
- Business Wire
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering
NEW BRUNSWICK, N.J. & SKILLMAN, N.J., May 03, 2023--Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue’s upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue’s common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to an additional 25,921,884 shares of its common stock to cover over-allotments, if any.
- Business Wire
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J., April 25, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39th Annual Strategic Decisions Conference on Wednesday, May 31st, at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).
- Business Wire
Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow
NEW BRUNSWICK, N.J., April 24, 2023--Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering ("IPO") of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expec
- Business Wire
Johnson & Johnson Reports Q1 2023 Results
NEW BRUNSWICK, N.J., April 18, 2023--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. "Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and lon
- Business Wire
Johnson & Johnson Subsidiary LTL Management LLC ("LTL") Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims
NEW BRUNSWICK, N.J., April 04, 2023--Johnson & Johnson (NYSE:JNJ) (the Company) today announced that its subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will equitably and efficiently resolve all claims arising from cosmetic talc litigation against the Company and its affiliates in North America. To that end, the Company has agreed to contribute up to a present value of $8.9 billion, payable over 25
- Business Wire
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
NEW BRUNSWICK, N.J., March 15, 2023--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.
- Business Wire
Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature
BEERSE, Belgium, March 15, 2023--The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical study, is now progressing into Phase 2 clinical studies for the prevention and treatment
- Business Wire
Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc.
NEW BRUNSWICK, N.J., March 08, 2023--Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, priced an offering of the following series of senior unsecured notes in an aggregate principal amount of $7.75 billion (each series of notes collectively, the "Notes"):
- Business Wire
Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors
NEW BRUNSWICK, N.J., February 14, 2023--Johnson & Johnson (NYSE: JNJ) announced today that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors.
- Business Wire
Johnson & Johnson to Participate in the Barclays Global HealthCare Conference
NEW BRUNSWICK, N.J., February 14, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global HealthCare Conference on Tuesday, March 14th, at the Loews Miami Beach Hotel, Miami Beach, Florida. Aldo Denti, Company Group Chairman DePuy Synthes and Peter Menziuso, Company Group Chairman, Vision will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).
- Business Wire
Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D
NEW BRUNSWICK, N.J., February 13, 2023--Johnson & Johnson (NYSE: JNJ) (the Company) today announced the appointment of John Reed, M.D., Ph.D., to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D. Dr. Reed previously served as Executive Vice President, Global Head of Research and Development for Sanofi and brings more than 35 years of biomedical research leadership to the Company.
- Business Wire
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
NEW BRUNSWICK, N.J., February 02, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 43rd Annual HealthCare Conference on Tuesday, March 7th, at the Boston Marriott Copley Place, Boston, MA. Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).
- Business Wire
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J., January 24, 2023--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johns
- Business Wire
Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference
NEW BRUNSWICK, N.J., January 18, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on Wednesday, February 15th. Biljana Naumovic, Worldwide Vice President, Oncology and Peter Lebowitz, Global Therapeutic Head, Oncology will represent the Company in a virtual session scheduled at 1:00 p.m. (Eastern Time).
- Business Wire
Johnson & Johnson Completes Acquisition of Abiomed
NEW BRUNSWICK, N.J., December 22, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.
- Business Wire
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
NEW BRUNSWICK, N.J., December 14, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. ("Offeror"), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the "Offer") to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ: ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitlin
- Business Wire
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J., December 13, 2022--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 24th to review fourth-quarter results. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer, and Jessica Moore, Vice President, Investor Relations will host the call.
- Business Wire
Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
NEW BRUNSWICK, N.J., December 07, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time).
- Business Wire
Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board
NEW BRUNSWICK, N.J., November 30, 2022--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief transitional period.
- Business Wire
Johnson & Johnson to Acquire Abiomed
NEW BRUNSWICK, N.J. & DANVERS, Mass., November 01, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an
- Business Wire
Johnson & Johnson Reports Q3 2022 Results
NEW BRUNSWICK, N.J., October 18, 2022--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. "Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses," said Joaquin Duato, Chief Executive Officer. "Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain con
- Business Wire
Johnson & Johnson to Participate in the Credit Suisse 31st Annual Healthcare Conference
NEW BRUNSWICK, N.J., October 03, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 31st Annual Global Healthcare Conference on Thursday, November 10th, 2022 at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 12:50 p.m. (Eastern Time).
- Business Wire
Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
NEW BRUNSWICK, N.J., September 28, 2022--Johnson & Johnson (the "Company") (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand.
- Business Wire
Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area
BRISBANE, Calif., September 20, 2022--Johnson & Johnson (NYSE: JNJ) (the Company) today opened its San Francisco Bay Campus, a state-of-the-art Research & Development (R&D) facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co
- Business Wire
Johnson & Johnson Announces $5 Billion Share Repurchase Program
NEW BRUNSWICK, N.J., September 14, 2022--Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock.
